Fortune.com has reported that EquiLend has found a buyer: private equity firm Welsh, Carson, Anderson & Stowe (WCAS). The $31 billion manager invests largely in health care and technology companies. The purchase price is said to be over US$800 million.
According to Fortune, “EquiLend generated 12-month EBITDA of more than $25 million and was expected to sell for over $700, Reuters reported in September. EquiLend is selling for roughly 25 to 30 times EBITDA, bankers said.”
WCAS announced a new fund raise of $5 billion in July 2023. The press release noted that “As with prior funds, WCAS XIV will seek to partner with proven management teams to acquire growing companies and drive value through operational improvements as well as organic and strategic M&A growth initiatives.”